Mantle Cell Lymphoma - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 426 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Mantle Cell Lymphoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Mantle Cell Lymphoma - Pipeline Review, H2 2016', provides an overview of the Mantle Cell Lymphoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Mantle Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mantle Cell Lymphoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
- The report reviews pipeline therapeutics for Mantle Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Mantle Cell Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Mantle Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Mantle Cell Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Mantle Cell Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for Mantle Cell Lymphoma - Overview 11
Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis 12
Mantle Cell Lymphoma - Therapeutics under Development by Companies 13
Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 17
Mantle Cell Lymphoma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Mantle Cell Lymphoma - Products under Development by Companies 21
Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes 26
Mantle Cell Lymphoma - Companies Involved in Therapeutics Development 27
AB Science SA 27
AbbVie Inc 28
Acetylon Pharmaceuticals, Inc. 29
Actinium Pharmaceuticals, Inc. 30
Affimed GmbH 31
Amgen Inc. 32
Asana BioSciences, LLC 33
Astellas Pharma Inc. 34
Astex Pharmaceuticals, Inc. 35
Bayer AG 36
BeiGene, Ltd. 37
Bristol-Myers Squibb Company 38
Celgene Corporation 39
Cellular Biomedicine Group, Inc. 40
Eisai Co., Ltd. 41
Eli Lilly and Company 42
EpiZyme, Inc. 43
Gilead Sciences, Inc. 44
GlaxoSmithKline Plc 45
Hutchison MediPharma Limited 46
ImmunoGen, Inc. 47
Immunomedics, Inc. 48
Incyte Corporation 49
Inflection Biosciences Limited 50
Johnson & Johnson 51
Juno Therapeutics Inc. 52
Karyopharm Therapeutics, Inc. 53
Kite Pharma, Inc. 54
LFB S.A. 55
MacroGenics, Inc. 56
MedImmune, LLC 57
Merck & Co., Inc. 58
Merck KGaA 59
Millennium Pharmaceuticals Inc 60
MorphoSys AG 61
Nordic Nanovector ASA 62
Novartis AG 63
Onconova Therapeutics, Inc. 64
Oncternal Therapeutics, Inc. 65
Patrys Limited 66
Pharmacyclics, Inc. 67
Portola Pharmaceuticals, Inc. 68
Seattle Genetics, Inc. 69
Selvita S.A. 70
Stemline Therapeutics, Inc. 71
Takeda Pharmaceutical Company Limited 72
TG Therapeutics, Inc. 73
Vivolux AB 74
Mantle Cell Lymphoma - Therapeutics Assessment 75
Assessment by Monotherapy Products 75
Assessment by Combination Products 76
Assessment by Target 77
Assessment by Mechanism of Action 82
Assessment by Route of Administration 87
Assessment by Molecule Type 89
Drug Profiles 91
(INCB-039110 + INCB-040093) - Drug Profile 91
13197 - Drug Profile 92
AB-8779 - Drug Profile 94
abexinostat hydrochloride - Drug Profile 95
acalabrutinib - Drug Profile 98
ACY-241 - Drug Profile 101
ACY-775 - Drug Profile 103
AFM-11 - Drug Profile 104
alisertib - Drug Profile 105
AMG-319 - Drug Profile 110
ASN-002 - Drug Profile 112
AT-7519 - Drug Profile 113
avicin d - Drug Profile 116
BC-8Y90 - Drug Profile 117
bendamustine hydrochloride - Drug Profile 118
Betalutin - Drug Profile 121
BGB-3111 - Drug Profile 125
BLyS-gel - Drug Profile 127
BMS-986016 - Drug Profile 128
buparlisib hydrochloride - Drug Profile 130
carfilzomib - Drug Profile 135
CBM-C19.1 - Drug Profile 147
CBM-C20.1 - Drug Profile 148
Cellular Immunotherapy for Oncology - Drug Profile 150
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 151
cerdulatinib - Drug Profile 152
copanlisib hydrochloride - Drug Profile 156
daratumumab - Drug Profile 160
denintuzumab mafodotin - Drug Profile 171
durvalumab - Drug Profile 174
E-7449 - Drug Profile 184
entospletinib - Drug Profile 185
epratuzumab - Drug Profile 187
EPZ-015666 - Drug Profile 194
HMPL-523 - Drug Profile 195
IBL-301 - Drug Profile 197
ibrutinib - Drug Profile 199
IGN-002 - Drug Profile 224
IMGN-529 - Drug Profile 226
IMMU-114 - Drug Profile 228
INA-01 - Drug Profile 230
INCB-40093 - Drug Profile 231
INCB-50465 - Drug Profile 232
inebilizumab - Drug Profile 233
inebilizumab + MEDI-0680 - Drug Profile 235
Iomab-B - Drug Profile 236
itacitinib adipate - Drug Profile 241
ixazomib citrate - Drug Profile 244
JCAR-014 - Drug Profile 253
JCAR-015 - Drug Profile 256
JCAR-017 - Drug Profile 261
JNJ-64052781 - Drug Profile 264
KTEC-19 - Drug Profile 266
LAM-002A - Drug Profile 273
M-7583 - Drug Profile 274
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 275
Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile 276
MOR-208 - Drug Profile 277
ON-123300 - Drug Profile 282
ONC-201 - Drug Profile 283
OSU-2S - Drug Profile 287
PATLM-1 - Drug Profile 288
PCAR-019 - Drug Profile 290
pembrolizumab - Drug Profile 291
ramucirumab - Drug Profile 322
ribociclib succinate - Drug Profile 332
S-055746 - Drug Profile 337
sapanisertib - Drug Profile 338
SEL-120 - Drug Profile 341
SEL-12034 - Drug Profile 343
SEL-24B489 - Drug Profile 345
selinexor - Drug Profile 346
SGN-CD70A - Drug Profile 363
SL-101 - Drug Profile 364
spebrutinib besylate - Drug Profile 365
TAK-659 - Drug Profile 367
TGR-1202 - Drug Profile 368
tisagenlecleucel-T - Drug Profile 375
tretinoin - Drug Profile 380
ublituximab - Drug Profile 381
UC-961 - Drug Profile 388
venetoclax - Drug Profile 390
VLX-1570 - Drug Profile 399
vorinostat - Drug Profile 401
Mantle Cell Lymphoma - Dormant Projects 405
Mantle Cell Lymphoma - Discontinued Products 408
Mantle Cell Lymphoma - Product Development Milestones 409
Featured News & Press Releases 409
Appendix 418
Methodology 418
Coverage 418
Secondary Research 418
Primary Research 418
Expert Panel Validation 418
Contact Us 418
Disclaimer 419

List of Tables

Number of Products under Development for Mantle Cell Lymphoma, H2 2016 18
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H2 2016 19
Number of Products under Development by Companies, H2 2016 20
Number of Products under Development by Companies, H2 2016 (Contd..1) 21
Number of Products under Development by Companies, H2 2016 (Contd..2) 22
Number of Products under Development by Companies, H2 2016 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2016 24
Comparative Analysis by Late Stage Development, H2 2016 25
Comparative Analysis by Clinical Stage Development, H2 2016 26
Comparative Analysis by Early Stage Development, H2 2016 27
Products under Development by Companies, H2 2016 28
Products under Development by Companies, H2 2016 (Contd..1) 29
Products under Development by Companies, H2 2016 (Contd..2) 30
Products under Development by Companies, H2 2016 (Contd..3) 31
Products under Development by Companies, H2 2016 (Contd..4) 32
Products under Investigation by Universities/Institutes, H2 2016 33
Mantle Cell Lymphoma - Pipeline by AB Science SA, H2 2016 34
Mantle Cell Lymphoma - Pipeline by AbbVie Inc, H2 2016 35
Mantle Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 36
Mantle Cell Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 37
Mantle Cell Lymphoma - Pipeline by Affimed GmbH , H2 2016 38
Mantle Cell Lymphoma - Pipeline by Amgen Inc., H2 2016 39
Mantle Cell Lymphoma - Pipeline by Asana BioSciences, LLC, H2 2016 40
Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H2 2016 41
Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2016 42
Mantle Cell Lymphoma - Pipeline by Bayer AG, H2 2016 43
Mantle Cell Lymphoma - Pipeline by BeiGene, Ltd., H2 2016 44
Mantle Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 45
Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H2 2016 46
Mantle Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 47
Mantle Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2016 48
Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H2 2016 49
Mantle Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2016 50
Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016 51
Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016 52
Mantle Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2016 53
Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2016 54
Mantle Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2016 55
Mantle Cell Lymphoma - Pipeline by Incyte Corporation, H2 2016 56
Mantle Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2016 57
Mantle Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2016 58
Mantle Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016 59
Mantle Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 60
Mantle Cell Lymphoma - Pipeline by Kite Pharma, Inc., H2 2016 61
Mantle Cell Lymphoma - Pipeline by LFB S.A., H2 2016 62
Mantle Cell Lymphoma - Pipeline by MacroGenics, Inc., H2 2016 63
Mantle Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2016 64
Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2016 65
Mantle Cell Lymphoma - Pipeline by Merck KGaA, H2 2016 66
Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 67
Mantle Cell Lymphoma - Pipeline by MorphoSys AG, H2 2016 68
Mantle Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016 69
Mantle Cell Lymphoma - Pipeline by Novartis AG, H2 2016 70
Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H2 2016 71
Mantle Cell Lymphoma - Pipeline by Oncternal Therapeutics, Inc., H2 2016 72
Mantle Cell Lymphoma - Pipeline by Patrys Limited, H2 2016 73
Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2016 74
Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2016 75
Mantle Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016 76
Mantle Cell Lymphoma - Pipeline by Selvita S.A., H2 2016 77
Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2016 78
Mantle Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 79
Mantle Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2016 80
Mantle Cell Lymphoma - Pipeline by Vivolux AB, H2 2016 81
Assessment by Monotherapy Products, H2 2016 82
Assessment by Combination Products, H2 2016 83
Number of Products by Stage and Target, H2 2016 85
Number of Products by Stage and Mechanism of Action, H2 2016 90
Number of Products by Stage and Route of Administration, H2 2016 95
Number of Products by Stage and Molecule Type, H2 2016 97
Mantle Cell Lymphoma - Dormant Projects, H2 2016 412
Mantle Cell Lymphoma - Dormant Projects (Contd..1), H2 2016 413
Mantle Cell Lymphoma - Dormant Projects (Contd..2), H2 2016 414
Mantle Cell Lymphoma - Discontinued Products, H2 2016 415